Neurocrine Biosciences (NBIX) Price to Sales (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Price to Sales for 16 consecutive years, with 17.86 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 1.35% year-over-year to 17.86; the trailing twelve-month figure through Jun 2026 stood at 5.08 (up 2.37% YoY), and the FY2025 full-year result was 4.96, down 13.84% from the prior year.
• Price to Sales rose to 17.86 in Q2 2026 per NBIX's latest filing, from 16.27 in the prior quarter.
• Across five years, Price to Sales topped out at 28.83 in Q1 2022 and bottomed at 16.27 in Q1 2026.
• Historically, Price to Sales has averaged 22.02 across 5 years, with a median of 21.88 in 2023.
• The sharpest annual moves came in 2024 and 2025: Price to Sales climbed 15.77% in 2024, then declined 28.98% in 2025.
• Over 5 years, Price to Sales stood at 27.98 in 2022, then fell by 9.77% to 25.24 in 2023, then dropped by 14.37% to 21.62 in 2024, then declined by 18.46% to 17.63 in 2025, then gained by 1.31% to 17.86 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 17.86, 16.27, and 17.63 for Q2 2026, Q1 2026, and Q4 2025 respectively.